# Harmony Pre-Announces Record Q2 2026 Revenue of ~$261M, CFO Steps Down

> news · REPORTED · 2026-07-16

On July 16, 2026, Harmony filed an 8-K pre-announcing record Q2 WAKIX net revenue of approximately $261 million, up 30% year-over-year, while reiterating full-year 2026 guidance of $1.0–$1.04 billion. The company simultaneously disclosed that CFO Glenn Reicin departed effective July 16, with SVP and Controller Stephen Mollichella named Interim Principal Financial Officer.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company that develops and commercializes therapies for patients with rare neurological diseases, led by its approved narcolepsy drug WAKIX (pitolisant).

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.sec.gov/Archives/edgar/data/0001802665/000110465926084095/hrmy-20260716xex99d1.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.